Risk Factors With Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy-Reply

JAMA Neurol. 2021 Jun 1;78(6):764-765. doi: 10.1001/jamaneurol.2021.0893.

Authors

Daniel B Rubin¹, Caron Jacobson², Henrikas Vaitkevicius^{3

4}

Affiliations

¹ Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
³ Brigham and Women's Hospital, Boston, Massachusetts.
⁴ Now with Clinical Development, Marinus Pharmaceuticals Inc, Radnor, Pennsylvania.

PMID: 33900372
DOI: 10.1001/jamaneurol.2021.0893

No abstract available

Publication types

Comment

MeSH terms

Cell- and Tissue-Based Therapy
Humans
Immunotherapy, Adoptive
Neurotoxicity Syndromes*
Receptors, Chimeric Antigen*
Risk Factors

Substances

Receptors, Chimeric Antigen

Grants and funding

G0601943/MRC_/Medical Research Council/United Kingdom